Sedia Biosciences

Executive Summary

Sedia Biosciences is a privately held diagnostics company headquartered in Beaverton, Oregon, specializing in point-of-care infectious disease testing and clinical specimen collection. Founded in 2009, the company has established a leading position in HIV recency testing, a critical tool for public health surveillance that distinguishes recent from long-term infections. Its flagship assay, the Sedia HIV-1 LAg-Avidity EIA, is widely used by global health organizations to monitor epidemic trends and evaluate prevention programs. In addition to HIV, Sedia develops assays for other infectious diseases and manufactures specimen collection devices, including dried blood spot cards, to enable remote testing and expand access to diagnostics in resource-limited settings. The company's mission is to advance global healthcare access through innovative, low-cost diagnostic solutions that can be deployed at the point of need. Despite being privately held and lacking publicly disclosed financials, Sedia has built a reputation as a reliable partner for public health agencies and NGOs. Key competitive advantages include its proprietary HIV recency technology, regulatory approvals in multiple countries, and established supply chain for global distribution. However, the company faces risks including dependence on HIV-related revenue, potential competition from emerging diagnostic platforms, and the need to continuously update its portfolio as disease prevalence shifts. Near-term growth is expected to be driven by expansion into new geographic markets, product line extensions (e.g., multiplex tests for co-infections), and strategic collaborations with global health initiatives. Sedia's focus on underserved populations and public health impact positions it well for steady but unspectacular growth, pending successful execution of its product roadmap.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval for a Next-Generation Point-of-Care HIV Recency Test70% success
• Q4 2026Major Partnership with Global Health Organization for HIV Surveillance Scale-Up80% success
• Q2 2026Launch of Advanced Dried Blood Spot Collection Device for Multi-Disease Testing60% success